CYP3A4 and Hypertension: In summary, the essential contraindications for ubrogepant include hypersensitivity to the drug, severe hepatic impairment, concurrent use of potent CYP3A4 inhibitors, pregnancy or breastfeeding, and uncontrolled hypertension.